TORONTO, Sept. 27, 2012 /CNW/ - RepliCel Life Sciences Inc.'s common
shares (RP) have been approved for listing on CNSX.
RepliCel is developing and patenting a new hair follicle cell
replication technology that has the potential to become the first
autologous cellular treatment for hair loss in men and women.
Listing and disclosure documents will be available in the Listings Disclosure Hall .
Trading Date: Monday, October 1, 2012
CUSIP: 76027P 10 3
ISIN: CA 76027P 10 3 6
SOURCE: Canadian National Stock Exchange (CNSX)
For further information:
If you have any questions or require further information please contact Radhika at (416) 572-2000 X 2435 or E-mail:email@example.com.